Urine

Dogs Thrive on Vegan Diets, Demonstrates the Most Comprehensive Study So Far

Retrieved on: 
tisdag, april 23, 2024
Urine, Dicarboxylic acid, Outline of health sciences, Vitamin D, Blood, Sustainability, Health, WINCHESTER, Biochemistry, PLOS, Vitamin, PLOS ONE, Overweight, Cat, Human, Greenhouse, Environment, Dog, Immunity, Dietary supplement

WINCHESTER, ENGLAND, Apr 24, 2024 - (ACN Newswire) - The longest, most comprehensive peer-reviewed study so far has demonstrated that dogs fed nutritionally-sound vegan diets maintain health outcomes as well as dogs fed meat.

Key Points: 
  • WINCHESTER, ENGLAND, Apr 24, 2024 - (ACN Newswire) - The longest, most comprehensive peer-reviewed study so far has demonstrated that dogs fed nutritionally-sound vegan diets maintain health outcomes as well as dogs fed meat.
  • The study was particularly interesting, given recent suggestions that peas might contribute to heart disease in dogs in the US.
  • In the current study, dogs were fed pea-based vegan pet food, for one year.
  • Our study offers new evidence on outcomes in clinically healthy dogs who thrive without consumption of animal-derived ingredients.

Travere Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on: 
måndag, maj 6, 2024
FDA, Total, Risk, Ligand Pharmaceuticals, European Commission, Research, UPCR, Webcast, HCU, IND, EGFR, PDUFA, SIMD, Civil service commission, Diagnosis, PMDA, GAAP, CMA, Congress, Table, PROTECT, Priority review, Food, Abstract, FSGS, Income tax, CSL Vifor, Quarter, Medication, Therapy, SAN, Plasma, Urine, International, Safety, Proteinuria, ANNA, Immunoglobulin A, Homocysteine, Investigational New Drug, Society, Shanda, New Drug Application, Genetic, European, Disease, Patient, Quality of life (healthcare), IPR, Bank statement, Growth, Pharmaceutical industry

Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.

Key Points: 
  • Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.
  • Travere Therapeutics will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET to discuss company updates as well as first quarter 2024 financial results.
  • The Company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results.

Studies Show Diabetes Medicine Can Cause Urologic Complications

Retrieved on: 
söndag, maj 5, 2024
Urine, Risk, American Urological Association, Abstract (summary), Abstract, MD, Research, Attention, Patient, Kidney, Albany Medical Center, Cardiovascular disease, Glucose, Annual general meeting, Chronic kidney disease, Urinary tract infection, SAN, Heart failure, Pharmaceutical industry

Researchers will present their study findings covering important updates on diabetes medicine and urologic complications in San Antonio, Texas, from May 3 to 6.

Key Points: 
  • Researchers will present their study findings covering important updates on diabetes medicine and urologic complications in San Antonio, Texas, from May 3 to 6.
  • “These meds are increasingly popular due to their ability to lower cardiovascular events and the risk of end stage renal disease.
  • They are now first line therapies for diabetes management in patients with cardiovascular disease, chronic kidney disease and heart failure,” said Dr. Inouye.
  • All three of these talks discuss the urologic sequelae we see in our clinics.”
    The following abstracts are covered in the moderated panel:

Hope and Healing: Bladder Cancer Awareness Month Starts Today

Retrieved on: 
onsdag, maj 1, 2024
Urine, Hope, Risk, Blood, Disease, Bladder cancer, Smoking, Patient, BCAN, BCAM, Cancer, Organization, Knowledge, Dietary supplement

BETHESDA, Md., May 1, 2024 /PRNewswire/ -- The Bladder Cancer Advocacy Network (BCAN) is proud to announce the start of Bladder Cancer Awareness Month (BCAM), 31 days in May dedicated to spotlighting one of the most common cancers in the United States. With an estimated 725,000 people living with bladder cancer and more than 80,000 new cases diagnosed each year, this month serves as a pivotal moment to bring attention to this disease.

Key Points: 
  • BETHESDA, Md., May 1, 2024 /PRNewswire/ -- The Bladder Cancer Advocacy Network (BCAN) is proud to announce the start of Bladder Cancer Awareness Month (BCAM), 31 days in May dedicated to spotlighting one of the most common cancers in the United States.
  • May 1st marks the beginning of Bladder Cancer Awareness Month.
  • BCAM is an opportunity for individuals and organizations to come together, fostering a supportive community for those impacted by bladder cancer.
  • BCAN invites everyone to participate in Bladder Cancer Awareness Month to make a difference in the lives of those impacted by this disease.

Neurocomplex-B Provides Comprehensive Energy Support

Retrieved on: 
måndag, april 29, 2024
Urine, Health, Crash, DNA, Immune system, Metabolism, Cell, System, Growth, NIH, Carbohydrate, Dietary supplement

FORT LAUDERDALE, Fla., April 29, 2024 /PRNewswire/ -- The vitamin B family is essential to bodily health and sustainable energy levels. Energy supplements like SYNEVIT®'s Neurocomplex-B can help by providing the body with the B vitamins it needs to function at a high level.

Key Points: 
  • Energy supplements like SYNEVIT®'s Neurocomplex-B can help by providing the body with the B vitamins it needs to function at a high level.
  • They help the body function more effectively, not through the direct provision of energy, but rather by setting the stage for the body to properly collect and expend energy through other functions.
  • Better Health explains that while B vitamins don't directly provide energy, "without B-group vitamins the body lacks energy.
  • "Neurocomplex-B fills gaps and provides comprehensive energy support," explains company founder and CEO George Cvetkovski.

CUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. V

Retrieved on: 
torsdag, maj 2, 2024
Urine, CFO, Ridge, Commander, U.S. Pacific Fleet, Acquisition

Mountain Crest V is the fifth vehicle in the Mountain Crest family of SPACs, the management of which has successfully completed four prior SPAC business combinations.

Key Points: 
  • Mountain Crest V is the fifth vehicle in the Mountain Crest family of SPACs, the management of which has successfully completed four prior SPAC business combinations.
  • Based on the non-binding term sheet, the pre-transaction equity value of CUBEBIO for the proposed business combination is $620 million, subject to adjustment depending on additional due diligence by Mountain Crest V and market conditions.
  • Dr. Suying Liu, Chairman, CEO and CFO of Mountain Crest V commented, “CUBEBIO‘s innovative diagnostic technology for cancer detection and active commercialization with contract in place point to significant growth potential.
  • We are excited to be partnering with CUBEBIO on this proposed business combination.”
    Eun-jong Choi, CEO of CUBEBIO emphasized, "We expect to execute a definitive merger agreement with Mountain Crest V, faithfully carry out the process for completing the business combination, and grow CUBEBIO into a global company by increasing corporate value."

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Retrieved on: 
onsdag, april 24, 2024
Urine, Kidney, FDA, Shanda, Embolism, Huber loss, Hepatic encephalopathy, Uric acid, Oliguria, Congestion, Blood volume, Furosemide, Organic acid, Deafness, Erythema, Cerebral edema, Ascites, Tinnitus, History, Thrombosis, Creatinine, NYHA, Dehydration, BUN, Patient, Hypersensitivity, Ototoxicity, Anuria, Glucose, Azotemia, Hypoproteinemia, CO2, Diuresis, Cirrhosis, Chronic kidney disease, Edema, Urinary retention, Bruise, Growth, Benign prostatic hyperplasia, Coma, Heart failure, Pharmaceutical industry

BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.

Key Points: 
  • The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility.
  • If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

American Kidney Fund Awards Fellowships to Researchers Studying Acute Interstitial Nephritis and Pulmonary Hypertension in Kidney Patients

Retrieved on: 
torsdag, april 11, 2024
Urine, Kidney disease, Cancer, Biomedical sciences, Inflammation, Biostatistics, MD–PhD, Kidney, Research fellow, Pulmonary hypertension, Nephritis, Risk, Hope, Blood, Clinical scientist, Epidemiology, Death, Immunotherapy, Clinical and Translational Science, MD, Research, Yale University, CSN, CKD, American Kidney Fund, Patient, Kidney transplantation, Bachelor of Arts, Dialysis, AKF, Diagnosis, Immune system, Chronic kidney disease, Heart failure, Pharmaceutical industry

However, it is common in patients with CKD, with approximately 21% of CKD patients having pulmonary hypertension.

Key Points: 
  • However, it is common in patients with CKD, with approximately 21% of CKD patients having pulmonary hypertension.
  • "Pulmonary hypertension is a common and underrecognized issue for patients with chronic kidney disease,” said Dr. Tuttle.
  • “Through this study, I plan to identify new risk factors for pulmonary hypertension in patients with chronic kidney disease.
  • Her current research focuses on the development of pulmonary hypertension in patients with chronic kidney disease.

Recce Pharmaceuticals Provides Business Update

Retrieved on: 
onsdag, april 10, 2024
Urine, FDA, Congress, Multi, WHO, Ecosystem, Safety, World Health Organization, Blood, Food, Burn, Poster, Infection, AMR, Partnership, Recce, Escherichia coli, Fungal infection, Research, Sputum, BIO, Development, IND, Pharmacology, Defense, Science, Society, MDR, Clinical trial, Annual general meeting, Antimalarial medication, Government, Therapy, Biotechnology, Investigational New Drug, Sepsis, Pharmaceutical industry

These achievements collectively position Recce on track with its upcoming IND application, underscoring the company's dedication to bringing novel therapies to market swiftly and responsibly.

Key Points: 
  • These achievements collectively position Recce on track with its upcoming IND application, underscoring the company's dedication to bringing novel therapies to market swiftly and responsibly.
  • Recce has been actively pursuing various grant applications and submissions, particularly in government antimicrobial resistance (AMR) initiatives and military and health security.
  • Recce delivered a company presentation at the request of the U.S. Biomedical Advanced Research and Development Authority (BARDA), further strengthening its relationship and collaboration with U.S. governmental organizations.
  • This acknowledgment highlights the potential of RECCE® compounds to address critical global health challenges posed by antibiotic-resistant bacteria.

United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com

Retrieved on: 
tisdag, april 23, 2024
Biotechnology, Surgery, Health, Genetics, Oncology, Liquid biopsy, Neoplasm, Nucleic acid thermodynamics, FDA, Urine, Breast cancer, CGP, NTRK, Prostate cancer, NIH, Woman, Blood, Entrectinib, Seminal vesicles, Gene, Liquid, Health care, Research, Plasma, Chinese, NGS, DNA, Lung, Incidence, Patient, Circulating tumor DNA, Diagnosis, Illumina, Inc., Biomarker, DCIS, NSCLC, Medical imaging

The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032.
  • These innovations enhance cancer detection and monitoring and propel the United States liquid biopsy market.
  • Breast cancer might stand out as a distinguished concern in the United States liquid biopsy market.